Clinical Pharmacokinetics

, Volume 25, Issue 6, pp 433–443 | Cite as

Lamotrigine Clinical Pharmacokinetics

  • Bernhard Rambeck
  • Peter Wolf
Review Article Drug Disposition

Summary

Lamotrigine is a new antiepileptic agent chemically unrelated to any established drugs in use. The drug can be estimated in biological fluids by high performance liquid chromatography and immunoassays. It is rapidly absorbed, reaching peak concentrations within about 3 hours postdose. The bioavailability of the oral formulation is about 98%. The area under the plasma concentration-time curve indicates dose-linear pharmacokinetics. The degree of plasma protein binding is 56%. Saliva concentrations are 46% of the plasma concentration. The concentration of lamotrigine in the brain is similar to the total concentration in the plasma.

Lamotrigine exhibits first-order linear kinetics during long term administration. 43 to 87% of a dose is recovered in the urine, predominantly as glucuronide metabolites. Mean half-lives of lamotrigine in healthy volunteers (single and multiple doses) as well as in epileptic patients receiving lamotrigine monotherapy range from 22.8 to 37.4 hours. Enzyme-inducing antiepileptic drugs such as phenytoin, phenobarbital (phenobarbitone) or carbamazepine reduce the half-life of lamotrigine (to mean values of 13.5 to 15 hours), whereas valproic acid increases the half-life of the drug (to mean values of 48.3 to 59 hours). Lamotrigine itself does not influence the plasma concentrations of concomitant antiepileptic drugs, except for causing an increase in concentrations of carbamazepine-10,11-epoxide, the main metabolite of carbamazepine. Other observations indicate that the interaction of carbamazepine and lamotrigine may be primarily pharmacodynamic rather than pharmacokinetic.

Usual dosages of lamotrigine range from 50 to 400 mg/day depending on an enzyme-inducing or -inhibiting comedication. Therapeutic plasma concentrations of the drug are not known, but a putative therapeutic range of 1 to 4 mg/L has been proposed. Some patients have tolerated concentrations >10 mg/L with benefit and without clinical toxicity. The value of measuring the concentrations of lamotrigine in helping to optimise the dosage or reduce the likelihood of adverse effects has not been established. Safety data from several large studies indicate that the incidence of adverse effects of the drug is low and that unwanted effects are reversible.

Keywords

High Performance Liquid Chromatography Carbamazepine Valproic Acid Antiepileptic Drug Lamotrigine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Betts T, Goodwin G, Withers RM, Yuen AWC. Human safety of lamotrigine. Epilepsia 32 (Suppl. 2): 17–21, 1991CrossRefGoogle Scholar
  2. Biddlecombe RA, Dean KL, Smith CD, Jeal SC. Validation of a radioimmunoassay for the determination of human plasma concentrations of lamotrigine. Journal of Pharmaceutical and Biomedical Analysis 8: 691–694, 1990PubMedCrossRefGoogle Scholar
  3. Binnie CD, Debets RMC, Engelsman M, Meijer JWA, Meinardi H, et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Research 4: 222–229, 1989PubMedCrossRefGoogle Scholar
  4. Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenite DGA, Korte RA, Meijer JWA, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 27: 248–254, 1986PubMedCrossRefGoogle Scholar
  5. Brodie MJ. Lamotrigine. Lancet 339: 1397–1400, 1992PubMedCrossRefGoogle Scholar
  6. Cheung H, Kamp D, Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Research 13: 107–112, 1992PubMedCrossRefGoogle Scholar
  7. Cociglio M, Alric R, Bouvier O. Performance analysis of a reversed-phase liquid Chromatographic assay of lamotrigine in plasma using solvent demixing extraction. Journal of Chromatography 572: 269–276, 1991PubMedCrossRefGoogle Scholar
  8. Cohen AF, Ashby L, Crowley D, Land G, Peck AW, et al. Lamotrigine (BW430C), a potential anticonvulsant: effects on the central nervous system in comparison with phenytoin and diazepam. British Journal of Clinical Pharmacology 20: 619–629, 1985PubMedCrossRefGoogle Scholar
  9. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clinical Pharmacology and Therapeutics 42: 535–541, 1987PubMedCrossRefGoogle Scholar
  10. Depot M, Powell JR, Messenheimer JA, Cloutier G, Dalton MJ. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clinical Pharmacology and Therapeutics 48: 346–355, 1990PubMedCrossRefGoogle Scholar
  11. Doig MV, Clare RA. Use of thermospray liquid chromatographymass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, lamotrigine. Journal of Chromatography 554: 181–189, 1991PubMedCrossRefGoogle Scholar
  12. Fazio A, Artesi C, Russo M, Trio R, Oteri G, et al. A liquid Chromatographic assay using a high-speed column for the determination of lamotrigine, a new antiepileptic drug, in human plasma. Therapeutic Drug Monitoring 14: 509–512, 1992PubMedCrossRefGoogle Scholar
  13. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 46: 152–176, 1993PubMedCrossRefGoogle Scholar
  14. Holdich T, Whiteman P, Orme M, Back D, Ward S. Effect of lamotrigine on pharmacology of the combined oral contraceptive pill. Epilepsia 32: 96, 1991CrossRefGoogle Scholar
  15. Jawad S, Oxley J, Yuen WC, Richens A. The effect of lamotrigine, a novel anticonvulsant, on interictal spikes in patients with epilepsy. British Journal of Clinical Pharmacology 22: 191–193, 1986PubMedCrossRefGoogle Scholar
  16. Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (lamictal) for refractory partial seizures. Epilepsia 30: 356–363, 1989PubMedCrossRefGoogle Scholar
  17. Jawad S, Yuen WC, Peck AW, Hamilton MJ, Oxley JR, et al. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Research 1: 194–201, 1987PubMedCrossRefGoogle Scholar
  18. Juergens U. Alkylamine/phosphoric acid as a universal buffer system for basic and acidic mobile phases in HPLC. Journal of Liquid Chromatography 11: 1925–1940, 1988CrossRefGoogle Scholar
  19. Juergens U, Meijer JWA, Land GS. An investigation into alternative HPLC methods to measure plasma lamotrigine. 11th Symposium on Column Liquid Chromatography, Amsterdam, 1987Google Scholar
  20. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug II: neurochemical studies on the mechanism of action. Epilepsia 27: 490–497, 1986PubMedCrossRefGoogle Scholar
  21. Loiseau P, Yuen AWC, Duche B, Menager T, Arnebes MC. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Research 7: 136–145, 1990PubMedCrossRefGoogle Scholar
  22. Magdalou J, Herber R, Bidault R, Siest G. In vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 260: 1166–1173, 1992PubMedGoogle Scholar
  23. Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, et al. Long-term tolerability, pharmacokinetics and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. Clinical Neuropharmacology 12: 312–321, 1989PubMedCrossRefGoogle Scholar
  24. Miller AA, Sawyer DA, Roth B, Peck AW, Leach MJ, et al. Lamotrigine. In Meldrum & Porter (Eds) New anticonvulsant drugs, pp. 165–177, John Libbey, London, 1986Google Scholar
  25. Panayiotopoulos CP, Ferrie CD, Knott C, Robinson RO. Interaction of lamotrigine with sodium valproate. Lancet 341: 445, 1993PubMedCrossRefGoogle Scholar
  26. Peck AW. Clinical pharmacology of lamotrigine. Epilepsia 32 (Suppl 2): 9–12, 1991CrossRefGoogle Scholar
  27. Pisani F, Di Perri R, Perucca E, Richens A. Interaction of lamotrigine with sodium valproate. Lancet 341: 1244, 1993CrossRefGoogle Scholar
  28. Posner J, Cohen AF, Land G, Winton C, Peck AW. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert’s syndrome). British Journal of Clinical Pharmacology 28: 117–120, 1989PubMedCrossRefGoogle Scholar
  29. Posner J, Holdich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. Journal of Pharmaceutical Medicine 1: 121–128, 1991aGoogle Scholar
  30. Posner J, Webster H, Yuen WC. Investigation on the ability of lamotrigine, a novel antiepileptic drug, to induce mixed function oxygenase enzymes. British Journal of Clinical Pharmacology 32: 658, 1991bCrossRefGoogle Scholar
  31. Ramsay RE, Pellock JM, Garnett WR, Sanchez RM, Valakas AM, et al. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Research 10: 191–200, 1991PubMedCrossRefGoogle Scholar
  32. Remmel RP, Sinz MW, Graves NM, Ritter FJ. Lamotrigine and lamotrigine-N-glucuronide concentrations in human blood and brain tissue. Seizure 1 (Suppl. A): P7/34, 1992Google Scholar
  33. Reutens DC, Duncan JS, Patsalos PN. Disabling tremor after lamotrigine with sodium valproate. Lancet 342: 185–186, 1993PubMedCrossRefGoogle Scholar
  34. Richens A. Pharmacokinetics of lamotrigine. In Richens (Ed.) Clinical update on lamotrigine: a novel antiepileptic agent, pp. 21–27, Wells Medical Limited, Kent, 1992Google Scholar
  35. Risner ME. Multicenter, double-blind, placebo-controlled, add-on, cross-over study of lamotrigine in epileptic outpatients with partial seizures. Epilepsia 31: 619–620, 1990Google Scholar
  36. Sailstadt JM, Findlay JWA. Immunofluorometric assay for lamotrigine in human plasma. Therapeutic Drug Monitoring 13: 433–442, 1991CrossRefGoogle Scholar
  37. Sander JWAS, Patsalos PN. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Research 13: 89–92, 1992PubMedCrossRefGoogle Scholar
  38. Sander JWAS, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC. A randomized double-blind controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Research 6: 221–226, 1990PubMedCrossRefGoogle Scholar
  39. Sinz M, Remmel RP. Analysis of lamotrigine and lamotrigine 2-N-glucuronide in guinea pig blood and urine by reversed-phase ion-pairing liquid chromatography. Journal of Chromatography 571: 217–230, 1991aPubMedCrossRefGoogle Scholar
  40. Sinz MW, Remmel RP. Isolation and characterisation of a novel quaternary ammonium-linked glucuronide of lamotrigine. Drug Metabolism and Disposition 19: 149–153, 1991bPubMedGoogle Scholar
  41. Warner T, Patsalos PN, Prevett M, Elyas AA, Duncan JS. Lamotrigine-induced carbamazepine toxicity; an interaction with carbamazepine-10,11-epoxide. Epilepsy Research 11: 147–150, 1992PubMedCrossRefGoogle Scholar
  42. Wolf P. Lamotrigine: preliminary clinical observations on pharmacokinetics and interactions with traditional antiepileptic drugs. Journal of Epilepsy 5: 73–79, 1992CrossRefGoogle Scholar
  43. Yuen A. Safety issues. In Richens (Ed.) Clinical update on lamotrigine: a novel antiepileptic agent, pp. 69–75, Wells Medical Limited, Kent UK, 1992Google Scholar
  44. Yuen AWC, Land G, Weatherley BC, Peck AW. Sodium valproate inhibits lamotrigine metabolism. British Journal of Clinical Pharmacology 33: 511–513, 1992PubMedCrossRefGoogle Scholar
  45. Yuen WC, Peck AW. Lamotrigine pharmacokinetics: oral and i.v. infusion in man. British Journal of Clinical Pharmacology 26: 242, 1988Google Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Bernhard Rambeck
    • 1
  • Peter Wolf
    • 1
  1. 1.Epilepsy-Centre Bethel and Department of BiochemistryGesellschaft für EpilepsieforschungBielefeldFederal Republic of Germany

Personalised recommendations